Nicotinamide Adenine Dinucleotide Based Therapeutics, Update.

Area of Science:

• Biochemistry
• Enzymology
• Drug Discovery

Background:

• Nicotinamide adenine dinucleotide (NAD(P)) dependent enzymes are vital for cellular homeostasis.
• The conserved NAD binding domain was thought to limit therapeutic selectivity.
• Recent findings reveal greater structural diversity, enabling selective inhibitor development.

Purpose of the Study:

• To review recent advancements in selective inhibitors of NAD(P)-dependent enzymes.
• To discuss therapeutic applications against parasitic and bacterial targets.
• To highlight progress in designing potent and efficient drug candidates.

Main Methods:

• Review of recent literature on NAD(P)-dependent enzyme inhibitors.
• Analysis of structural diversity in NAD(P)-binding domains.
• Discussion of therapeutic strategies and drug development pipelines.

Main Results:

• Numerous potent and selective inhibitors of NAD(P)-dependent enzymes have been reported.
• Progress in developing therapies against Cryptosporidium parvum and new antibiotics.
• Identification of novel inhibitors for bacterial NAD-ligases, NAD-kinases, and transferases.

Conclusions:

• Selective inhibitors of NAD(P)-dependent enzymes represent a promising therapeutic avenue.
• Further research is crucial for translating these compounds into clinical applications.
• Understanding structural factors is key to designing more effective drug candidates.